RT Journal Article
T1 Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
A1 Sen, Abhijit
A1 Papadimitriou, Nikos
A1 Lagiou, Pagona
A1 Perez-Cornago, Aurora
A1 Travis, Ruth C
A1 Key, Timothy J
A1 Murphy, Neil
A1 Gunter, Marc
A1 Freisling, Heinz
A1 Tzoulaki, Ioanna
A1 Muller, David C
A1 Cross, Amanda J
A1 Lopez, David S
A1 Bergmann, Manuela
A1 Boeing, Heiner
A1 Bamia, Christina
A1 Kotanidou, Anastasia
A1 Karakatsani, Anna
A1 Tjønneland, Anne
A1 Kyrø, Cecilie
A1 Outzen, Malene
A1 Redondo, María-Luisa
A1 Cayssials, Valerie
A1 Chirlaque, Maria-Dolores
A1 Barricarte, Aurelio
A1 Sanchez-Perez, Maria-Jose
A1 Larrañaga, Nerea
A1 Tumino, Rosario
A1 Grioni, Sara
A1 Palli, Domenico
A1 Caini, Saverio
A1 Sacerdote, Carlotta
A1 Bueno-de-Mesquita, Bas
A1 Kühn, Tilman
A1 Kaaks, Rudolf
A1 Nilsson, Lena Maria
A1 Landberg, Rikard
A1 Wallström, Peter
A1 Drake, Isabel
A1 Bech, Bodil Hammer
A1 Overvad, Kim
A1 Aune, Dagfinn
A1 Khaw, Kay-Tee
A1 Riboli, Elio
A1 Trichopoulos, Dimitrios
A1 Trichopoulou, Antonia
A1 Tsilidis, Konstantinos K
K1 EPIC
K1 caffeinated
K1 coffee
K1 decaffeinated
K1 prostate cancer
K1 tea
AB The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94-1.09) and 0.98 (95% CI, 0.90-1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79-1.21) and 0.89 (95% CI, 0.70-1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.
YR 2018
FD 2018-11-16
LK http://hdl.handle.net/10668/12643
UL http://hdl.handle.net/10668/12643
LA en
DS RISalud
RD Apr 14, 2025